{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:52:46Z","timestamp":1792788766424,"version":"4.5.0"},"reference-count":19,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:00:00Z","timestamp":1609372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shire Deutschland GmbH"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lysosomal Storage Diseases (LSD) are rare and multisytemic diseases which are caused by lysosomal enzyme deficiencies leading into accumulation of waste products due to an interruption in the decomposition process. Due to the low prevalence and therefore limited disease awareness as well as the fact that LSD patients present with unspecific symptoms the final diagnosis is often made after a long delay. The aim of this German-wide survey was to characterize the period between onset of symptoms and final diagnosis regarding e.g. self-perceived health, symptom burden and false diagnoses for patients with selected LSDs (Fabry disease (FD), Gaucher disease (GD) and Mucopolysaccharidosis type II (MPS II).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study was conducted as a telephone based cross-sectional survey. All patients living in Germany with a confirmed diagnosis of FD, GD or MPS II were eligible to participate. The questionnaire was provided in advance in order to enable the participants to prepare for the interview. Only descriptive analyses were carried out. Single analyses were not carried out for all three patient groups due low case numbers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the overall population, 39 patients have been diagnosed with FD, 19 with GD and 11 with MPS II with the majority of patients being index patients. The majority of FD patients reported their current health status as \u201csatisfactory\u201d or better (79.5%). Self-perceived health status was observed to be at least stable or improving for the majority of FD patients compared to the year prior to diagnosis. The most frequently reported symptoms for patients with FD were paraesthesias (51.3%), whereas patients with GD reported a tendency for bleeding, blue spots or coagulation disorder (63.2%) as well as hepatomegaly and\/or splenomegaly (63.2%) as the most commonly appearing symptoms. The number of patients reporting misdiagnoses was n = 5 (13.5%) for patients with FD and n = 5 (27.8%) for patients with GD. The median duration of the diagnostic delay was 21.0 years for FD, 20.0 years for GD and 2.0 years for MPS II.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study showed that self-perceived status of health for patients might improve once the final correct diagnoses has been made and specific treatment was available. Furthermore, it was observed that diagnostic delay is still high in Germany for a relevant proportion of affected patients. Further challenges in the future will still be to increase awareness for these diseases across the entire healthcare sector to minimize the diagnostic delay.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0244279","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T15:28:05Z","timestamp":1609428485000},"page":"e0244279","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["The patient journey of patients with Fabry disease, Gaucher disease and Mucopolysaccharidosis type II: A German-wide telephone survey"],"prefix":"10.1371","volume":"15","author":[{"given":"Eugen","family":"Mengel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Gaedeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Gothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Krupka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Reinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2868-5211","authenticated-orcid":true,"given":"Christoph","family":"Ohlmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,12,31]]},"reference":[{"key":"pone.0244279.ref001","unstructured":"Bundesgesundheitsministerium f\u00fcr Gesundheit. Seltene Erkrankungen 2019 [updated 27.05.201916.08.2019]. https:\/\/www.bundesgesundheitsministerium.de\/themen\/praevention\/gesundheitsgefahren\/seltene-erkrankungen.html#c3521."},{"issue":"4","key":"pone.0244279.ref002","first-page":"145","article-title":"Lysosomal storage diseases: heterogeneous group of disorders","volume":"3","author":"DA Wenger","year":"2013","journal-title":"BioImpacts"},{"issue":"3","key":"pone.0244279.ref003","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ymgme.2017.08.002","article-title":"Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians","volume":"122","author":"A Mehta","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"8","key":"pone.0244279.ref004","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.tins.2011.05.006","article-title":"Clarifying lysosomal storage diseases","volume":"34","author":"ML Schultz","year":"2011","journal-title":"Trends Neurosci"},{"key":"pone.0244279.ref005","volume-title":"Epidemiology of lysosomal storage diseases: an overview","author":"M Fuller","year":"2006"},{"key":"pone.0244279.ref006","unstructured":"OrphaNet. Fabry Disease 2012. https:\/\/www.orpha.net\/consor\/cgi-bin\/Disease_Search.php?lng=DE&data_id=94."},{"key":"pone.0244279.ref007","unstructured":"OrphaNet. MPS II 2007. https:\/\/www.orpha.net\/consor\/cgi-bin\/Disease_Search.php?lng=EN&data_id=131."},{"issue":"2","key":"pone.0244279.ref008","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jpeds.2011.01.054","article-title":"Prevalence and Characterization of Cardiac Involvement in Hunter Syndrome","volume":"159","author":"C Kampmann","year":"2011","journal-title":"J Pediatr"},{"key":"pone.0244279.ref009","unstructured":"OrphaNet. Gaucher Disease 2006. https:\/\/www.orpha.net\/consor\/cgi-bin\/Disease_Search.php?lng=DE&data_id=644."},{"key":"pone.0244279.ref010","unstructured":"Beck M, vom Dahl S, Mengel E, Niederau C, Poll L, Arndt R. Leitlinie zur Diagnostik und Therapie des M Gaucher. 20074. https:\/\/www.orpha.net\/consor\/cgi-bin\/Disease_Search.php?lng=EN&data_id=131."},{"issue":"1","key":"pone.0244279.ref011","article-title":"Time delays in the diagnosis and treatment of Fabry disease","volume":"71","author":"R Resin","year":"2017","journal-title":"Int J Clin Prac"},{"issue":"10","key":"pone.0244279.ref012","first-page":"1216","article-title":"Measures to improve the healthsituation of patients with rare diseases in Germany: A comparison with the National Action Plan","volume":"57","author":"M Frank","year":"2014","journal-title":"Bundesgesundheitsblatt"},{"issue":"3","key":"pone.0244279.ref013","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"A Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"issue":"68","key":"pone.0244279.ref014","article-title":"Australian children living with rare diseases: experiences of diagnosis and perceived consequences of diagnostic delays","volume":"12","author":"Y Zurynski","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"pone.0244279.ref015","unstructured":"Kole A, Faurisson F. The Voice of 12,000 Patients. Experiences and Expectations of Rare Disease Patients on Diagnosis and Care in Europ: Eurodis; 2009. p. 324."},{"key":"pone.0244279.ref016","unstructured":"German Socio-Economic Panel (SOEP). TNS Infratest Sozialforschung. Erhebungsinstrumente des IAB-SOEP Migrationssamples 2016. 2193\u20135580. Berlin: 2016."},{"issue":"7","key":"pone.0244279.ref017","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/GIM.0b013e31817701e6","article-title":"Initial report from the Hunter Outcome Survey","volume":"10","author":"JE Wraith","year":"2008","journal-title":"Genet Med"},{"issue":"2","key":"pone.0244279.ref018","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ajh.24957","article-title":"Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)","volume":"93","author":"A Zimran","year":"2018","journal-title":"Am J Hematol"},{"key":"pone.0244279.ref019","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13601-018-0229-4","article-title":"Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey","volume":"8","author":"A Zanichelli","year":"2018","journal-title":"Clin Transl Allergy"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0244279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T15:28:19Z","timestamp":1609428499000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0244279"}},"subtitle":[],"editor":[{"given":"John Lynn","family":"Jefferies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0244279","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,31]]}}}